Safety, pharmacokinetic, and functional effects of the nogo-a monoclonal antibody in amyotrophic lateral sclerosis: a randomized, first-in-human clinical trial
about
Ozanezumab dose selection for amyotrophic lateral sclerosis by pharmacokinetic-pharmacodynamic modelling of immunohistochemistry data from patient muscle biopsiesTreatment of rats with an anti-(+)-methamphetamine monoclonal antibody shortens the duration of action of repeated (+)-methamphetamine challenges over a one month periodUse of biomarkers in ALS drug development and clinical trialsConcise Review: Bridging the Gap: Novel Neuroregenerative and Neuroprotective Strategies in Spinal Cord Injury.Nogo receptor complex expression dynamics in the inflammatory foci of central nervous system experimental autoimmune demyelination.Experimental trials in amyotrophic lateral sclerosis: a review of recently completed, ongoing and planned trials using existing and novel drugs.Promoting recovery from ischemic stroke.Drugs in clinical development for the treatment of amyotrophic lateral sclerosis.Amyotrophic Lateral Sclerosis, 2016: existing therapies and the ongoing search for neuroprotection.Pathogenesis of amyotrophic lateral sclerosis.Nogo-A Antibodies for Progressive Multiple Sclerosis.Restoring brain function after stroke - bridging the gap between animals and humans.Spatiotemporal and Long Lasting Modulation of 11 Key Nogo Signaling Genes in Response to Strong Neuroexcitation.p75NTR and TROY: Uncharted Roles of Nogo Receptor Complex in Experimental Autoimmune Encephalomyelitis.Anti-Nogo-A antibody: a treatment option for neurogenic lower urinary tract dysfunction?
P2860
Q28543591-5C7978AE-A4D5-4633-92A7-F8F3AFAB76B9Q34602548-5F249C80-EBC3-492F-964D-FD0407CE4469Q36733981-6533EE88-73B8-49E5-8031-35CF23BF98DFQ37042664-E1469CC4-B414-4336-B2F2-81707540E396Q37325616-2C92DE14-0A32-4843-BA38-68E13C6C9E8FQ38223292-CD554EC8-6510-4207-9E2D-F5ED17D843E1Q38675024-B671851E-7783-4DDC-9842-6D430F1E432AQ38748144-F172F5F8-66E6-4300-A32A-28C1B3D1BB6EQ38847200-C8EF2604-2B74-4F61-84D3-B5FD78CBEC21Q38906347-09D8CCE8-0C1C-46ED-A213-74E4DD6BA139Q39010894-BA7F42D1-927C-4A17-BD9D-7FAEC8C149ACQ39183467-04ED289F-5338-4C2E-9F39-D9BA243AFAA8Q42014342-111474BD-633D-4B00-BB2C-CC6AC9DDF73BQ48320605-BC29C5C4-4D3D-4C89-85FC-EEE61FFA1315Q48445228-BB0EB764-9CCB-4A4C-ADBF-F7AC008FBD31
P2860
Safety, pharmacokinetic, and functional effects of the nogo-a monoclonal antibody in amyotrophic lateral sclerosis: a randomized, first-in-human clinical trial
description
2014 nî lūn-bûn
@nan
2014 թուականին հրատարակուած գիտական յօդուած
@hyw
2014 թվականին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Safety, pharmacokinetic, and f ...... first-in-human clinical trial
@ast
Safety, pharmacokinetic, and f ...... first-in-human clinical trial
@en
Safety, pharmacokinetic, and f ...... first-in-human clinical trial
@nl
type
label
Safety, pharmacokinetic, and f ...... first-in-human clinical trial
@ast
Safety, pharmacokinetic, and f ...... first-in-human clinical trial
@en
Safety, pharmacokinetic, and f ...... first-in-human clinical trial
@nl
prefLabel
Safety, pharmacokinetic, and f ...... first-in-human clinical trial
@ast
Safety, pharmacokinetic, and f ...... first-in-human clinical trial
@en
Safety, pharmacokinetic, and f ...... first-in-human clinical trial
@nl
P2093
P2860
P50
P921
P3181
P1433
P1476
Safety, pharmacokinetic, and f ...... first-in-human clinical trial
@en
P2093
Alienor Berges
Andrea Corse
Arseniy Lavrov
Bams Abila
Benjamin Rix Brooks
Dale Lange
David Krull
Gary Peters
Guy Meno-Tetang
Jeffrey D Rothstein
P2860
P304
P3181
P356
10.1371/JOURNAL.PONE.0097803
P407
P577
2014-01-01T00:00:00Z